Medtronic and Lilly Form Alliance to Provide Solutions for Diabetes Management

Collaboration Combines Insulin Expertise of Lilly with Medtronic Delivery and
Glucose Sensing Leadership
MINNEAPOLIS & INDIANAPOLIS--(Business Wire)--
Two of the most recognized names in diabetes management - Medtronic, Inc.
(NYSE:MDT) and Eli Lilly and Company (NYSE:LLY) - today announced a strategic
marketing collaboration to bolster each company`s commitment to help people with
diabetes manage their blood sugar using insulin therapy.

Working collaboratively with health care professionals, Medtronic and Lilly
marketing and sales operations in the United States will work to improve the
delivery of diabetes education for insulin-taking patients and their caregivers.
This includes the development of new educational resources and classes around
the initiation and intensive management of insulin, insulin pump therapy and
continuous glucose monitoring (CGM).

The alliance combines the insulin expertise of Lilly - a worldwide leader in
diabetes treatment, research and education - with the advanced diabetes
technologies of Medtronic, the world`s largest manufacturer of insulin pumps and
CGM, and maker of the world`s only integrated diabetes management system that
combines the power of insulin pump therapy with CGM.

"Medtronic and Lilly are joining together to help improve patient access to
high-quality diabetes education," said Chris O`Connell, president of the
Diabetes business unit and senior vice president at Medtronic. "Because diabetes
management is complicated, it is crucial that physicians and patients have the
best access to information and educational resources. This collaboration will
generate greater awareness and enable more people to benefit from the latest
educational tools regarding insulin pump therapy and continuous glucose
monitoring."

"People with diabetes have numerous treatment options and devices to help manage
blood sugar, but physicians and patients need resources and solutions to
integrate these improvements into real-world therapy," said Matt Beebe, Diabetes
brand leader, Lilly USA, LLC. "With this alliance, Lilly and Medtronic hope to
create integrated solutions to address challenges for people taking insulin who
need optimal glycemic control. By joining forces, we will help make insulin
therapy more achievable by offering new educational materials and resources that
help make insulin pump therapy fit into patients` lives."

Both companies are dedicated to improving the overall patient experience and
bring trusted reputations along with a history of firsts in diabetes care.

Medtronic has been well-established as the leader in insulin delivery innovation
since it introduced its first insulin pump in 1983, and has been improving on
the technology for more than 25 years. Medtronic continued to innovate with the
first CGM system approved for physician use in 1999, the first patient-use CGM
in 2003 and the most advanced Web-based therapy management system in 2004. Lilly
has long been the leading innovator in insulin therapy; Lilly introduced the
world`s first insulin for public use in 1923 and has continued to introduce
advances in diabetes therapy over the next 85 years.

About Diabetes

According to the Centers for Disease Control and Prevention, diabetes affects
nearly 24 million Americans; of that, nearly one-quarter, or nearly six million
people, do not know they have the disease.1 Diabetes is the sixth leading cause
of death in the United States and costs approximately $174 billion per year in
direct and indirect medical expenses.1,2

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering
industry-leading solutions to support people living with and treating diabetes.
Lilly introduced the world`s first commercial insulin in 1923, and remains at
the forefront of medical and delivery device innovation to manage diabetes.
Lilly is also committed to providing solutions beyond therapy -- practical
tools, education and support programs to help overcome barriers to success along
the diabetes journey. At Lilly, the journey of each person living with or
treating diabetes inspires ours. For more information, visit
www.lillydiabetes.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and information
-- for some of the world's most urgent medical needs. Information about Lilly is
available at www.lilly.com.

About the Diabetes Business at Medtronic

The Diabetes business at Medtronic (www.medtronicdiabetes.com) is the world
leader in advanced diabetes management solutions, including integrated diabetes
management systems, insulin pump therapy, continuous glucose monitoring systems
and therapy management software.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global
leader in medical technology, alleviating pain, restoring health and extending
life for millions of people around the world.

1 Centers for Disease Control and Prevention (CDC). National diabetes fact
sheet: general information and national estimates on diabetes in the United
States, 2007. Rev ed. Atlanta, GA: U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, 2008

2 American Diabetes Association. Direct and indirect costs of diabetes in the
United States. Available at:
http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. Accessed
January 16, 2009

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic`s Annual Report on Form 10-K for the year ended
April 25, 2008.Actual results may differ materially from anticipated results.

Lilly
J. Scott MacGregor
Public Relations
317-651-1494
Mobile: 317-440-4699
or
Medtronic
Steve Sabicer
Public Relations
818-576-4826
Mobile: 714-907-6264
or
Jeff Warren
Investor Relations
763-505-2696

Copyright Business Wire 2009